Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Connect Biopharma (Nasdaq: CNTB) management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40 p.m. ET.

Rhea-AI Summary

Connect Biopharma (Nasdaq: CNTB) management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40 p.m. ET.

A live webcast will be available via the Investors section of the company website at investors.connectbiopharma.com, with an archived replay accessible for approximately 90 days after the conference.

Argus Feb 19 session

-1.02% close to close Open Argus

Details

News Market Reaction – CNTB

In the Feb 19 session, CNTB declined 1.02%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights CNTB’s participation in the Oppenheimer conference, extending its patte...

Analysis

This announcement highlights CNTB’s participation in the Oppenheimer conference, extending its pattern of using investor and medical meetings to spotlight rademikibart and its inflammatory-disease pipeline. Against a backdrop of prior ERS data releases, Q3 2025 results showing a $17.2M net loss and $54.8M in cash, and sizable disclosed shareholders, investors may focus on upcoming Phase 2 readouts and capital needs rather than this visibility-focused event alone.

Key Figures

Cash & investments: $54.8M Net loss: $17.2M Operating expenses: $17.7M +5 more

Cash & investments

$54.8M

As of Sept 30, 2025 (Q3 2025 10-Q)

Net loss

$17.2M

Q3 2025 (three months ended Sept 30, 2025)

Operating expenses

$17.7M

Q3 2025 total operating expenses

R&D expense

$11.1M

Q3 2025 research and development

G&A expense

$6.6M

Q3 2025 general and administrative

Loss per share

$0.31

Q3 2025 basic and diluted loss per share

Shares outstanding

55,903,513

Ordinary shares outstanding as of Oct 31, 2025

Beneficial ownership

10.8%

Wubin Pan stake as of Dec 31, 2025 (Schedule 13G/A)

Historical Context

5 past events · Latest: Jan 12

5 events

1. Jan 12

   MOA/data update

   24h Move

   -1.4%

   Highlighted new rademikibart mechanism data and outlined 2026 clinical priorities.

2. Nov 24

   Conference participation

   24h Move

   -4.3%

   Announced fireside chat at the 8th Annual Evercore Healthcare Conference.

3. Nov 12

   Earnings update

   24h Move

   +5.9%

   Reported Q3 2025 results and business update with ongoing Phase 2 programs.

4. Sep 29

   Clinical data update

   24h Move

   -16.6%

   Presented Phase 2b rademikibart data with significant FEV1 gains and fewer exacerbations.

5. Sep 04

   Conference preview

   24h Move

   -10.6%

   Announced two upcoming ERS 2025 poster presentations on rademikibart in asthma.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26^th, 2026 at 2:40 p.m. ET.

The live webcast of the presentation may be accessed via the Investors section of the Connect website at investors.connectbiopharma.com. An archived replay of the event will be available on the website for approximately 90 days following the conference.

About Connect Biopharma
Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα. The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Connect has granted an exclusive license to Simcere Pharmaceutical Co., Ltd., for rademikibart in Greater China. Under the exclusive license and collaboration agreement, Connect is eligible to receive remaining milestone payments up to an aggregate amount of approximately $110 million upon the achievement of certain development, regulatory and commercial milestones. Connect is also eligible to receive royalties at tiered percentage rates up to low double-digit percentages on net sales in Greater China.

For more information visit www.connectbiopharma.com.

Investor Relations Contact:
Alex Lobo
Precision AQ
Alex.lobo@precisionaq.com
(212) 698-8802

Media Contact:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Connect Biopharma (CNTB) present at the Oppenheimer Healthcare Life Sciences conference?

Connect Biopharma will present on Thursday, February 26, 2026 at 2:40 p.m. ET. According to the company, management plans to deliver the presentation at that scheduled time during the Oppenheimer 36th Annual Healthcare Life Sciences Conference.

How can investors watch Connect Biopharma's (CNTB) Oppenheimer conference presentation?

Investors can watch a live webcast at investors.connectbiopharma.com at the scheduled time. According to the company, the live stream will be accessible via the Investors section of its website for real‑time viewing.

Will Connect Biopharma (CNTB) provide a replay of the Oppenheimer presentation and for how long?

Yes, an archived replay will be posted and available for approximately 90 days following the conference. According to the company, the replay will be hosted on the investor website for on‑demand access during that period.

What topics will Connect Biopharma (CNTB) cover at the February 26, 2026 presentation?

The company will present management remarks and updates relevant to its clinical-stage programs and strategy. According to the company, the presentation will cover recent developments and corporate outlook for investors at the conference.

Where is the webcast of Connect Biopharma's (CNTB) presentation hosted?

The webcast is hosted on the company's investor website at investors.connectbiopharma.com. According to the company, both the live webcast and the archived replay will be available through that Investors section.

Is the Connect Biopharma (CNTB) Oppenheimer presentation open to the public or only to registered attendees?

The presentation will be available via a public live webcast on the investor website, enabling remote access. According to the company, viewers can watch the session online without attending the conference in person.